GLP-1-based medications, such as tirzepatide, have gained immense popularity for their role in reducing obesity nationwide. However, emerging research raises concerns about the sustainability of their benefits once treatment stops.

A recent study published in JAMA Internal Medicine reveals that most participants who discontinued tirzepatide experienced significant weight regain. More worryingly, their cardiovascular and metabolic health markers—like blood pressure, cholesterol, and blood sugar control—also reverted to pre-treatment levels.

Experts from the University of Pittsburgh argue that these findings highlight the need to rethink how we view these drugs. Elizabeth Oczypok and Timothy Anderson suggest shifting their label from “weight loss” to “weight management” medications, implying continuous use may be necessary for lasting effects. This perspective aligns with broader research indicating that stopping these drugs often leads to rapid weight regain and health declines.

For those considering or currently using GLP-1 drugs, understanding that these are likely long-term solutions rather than quick fixes is crucial. Medical professionals recommend consulting healthcare providers to develop sustainable, personalized weight management strategies.

David Nield

Dave is a freelance tech journalist with over 20 years covering gadgets, apps, and the web. From Stockport, England, he covers news, features, and reviews for TechRadar, focusing on phones, tablets, and wearables. He ensures top weekend breaking news and has bylines at Gizmodo, T3, PopSci, and others. He edited PC Explorer and The Hardware Handbook for years. Read me on x.com or linkedin.